IDH1 Mutation Throws Door Open on AML Research

Fri, 04/16/2010 - 03:30

We at Novus Biologicals have a large antibody database for cancer research. However, AML, or acute myeloid leukaemia, is one of the cancers for which the number of antibodies is still fairly small, owing to limited knowledge of the genes involved.

An exciting new discovery looks set to change all that. Recently, Thompson et al of Abramson Cancer Centre, Pennsylvania University, discovered mutated IDH1, or isocitrate dehydrogenase 1, in stock AML cells. The biomarker was 2HG (2-hydroxyglutarate), a metabolite specific only to the mutated form of IDH1. The results indicated that mutated IDH1 could account for up to 50% of all AML cases where a gene had previously not been identified.

Western Blot: Isocitrate dehydrogenase Antibody Western Blot: Isocitrate dehydrogenase Antibody

In its non-mutated form, IDH1 plays an important role in the tertiary stage of the citric acid cycle. However, when mutated it acquires a novel metabolic function that results in the release of 2HG. Although both 2HG and mutated IDH1 had been shown to be overexpressed in tumour cells, it was only in November 2009 that the role of mutated IDH1 as an oncogene was ascertained, when 2HG was identified as a metabolite, and therefore biomarker for the gene in brain tumour studies. Prior to this, IDH1 was thought to have a non-functional role in tumour formation.

Cancer metabolism, in which antibody assays concentrate on the metabolic changes that take place in cancer cells, is an exciting new area that has enormous implications in the development of novel therapeutic compounds. This latest news has opened up new avenues of exploration for antibody suppliers like us at Novus Biologicals.

Novus Biologicals offers many Isocitrate dehydrogenase reagents for your research needs including:


Greаt delivery. Sound arguments. Kеep uρ the great wоrk.

Blog Topics